Related references
Note: Only part of the references are listed.Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl et al.
IMMUNOBIOLOGY (2017)
Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors
Anja Derer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Hans-Peter Gerber et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
Gang An et al.
BLOOD (2016)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Myeloid-derived suppressor cells: The green light for myeloma immune escape
Ehsan Malek et al.
BLOOD REVIEWS (2016)
IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
Philippos Perimenis et al.
BMC CANCER (2016)
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2016)
CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy for B-Cell Malignancies
C. J. Turtle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program
P. L. Zinzani et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Immunotherapy advances in uro-genital malignancies
Raffaele Ratta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Monitoring immune responses in the tumor microenvironment
Jennifer A. Wargo et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Antibody drug conjugates: the future of chemotherapy?
Edith Borcoman et al.
CURRENT OPINION IN ONCOLOGY (2016)
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
Eri Matsuki et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
Jon Bjoern et al.
CYTOTHERAPY (2016)
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
Lavinia Spain et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors
Julius Strauss et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma
Nabila Bennani-Baiti et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines
T. J. Vreeland et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions
Matthew Zibelman et al.
IMMUNOTHERAPY (2016)
Roles of regulatory T cells in cancer immunity
Yoshiko Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2016)
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer
Sung-Bae Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Immunological off-target effects of imatinib
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Maria I. Carlo et al.
NATURE REVIEWS UROLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
Letizia Gandolfi et al.
ONCOLOGIST (2016)
Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia
Constantine S. Tam et al.
SEMINARS IN ONCOLOGY (2016)
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Benjamin V. Park et al.
CANCER DISCOVERY (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Antibody Drug Conjugates for Cancer Therapy
Paul Polakis
PHARMACOLOGICAL REVIEWS (2016)
Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
Meagan S. Barbee et al.
ANNALS OF PHARMACOTHERAPY (2015)
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
Andrew W. Roberts et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Emerging therapeutic targets in bladder cancer
Benedito A. Carneiro et al.
CANCER TREATMENT REVIEWS (2015)
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
Valsamo K. Anagnostou et al.
CLINICAL CANCER RESEARCH (2015)
Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications
Angela Esposito et al.
CURRENT OPINION IN ONCOLOGY (2015)
Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment
Farhadul Islam et al.
EXPERIMENTAL CELL RESEARCH (2015)
Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia
Alla Dolnikov et al.
EXPERIMENTAL HEMATOLOGY (2015)
Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond
Yin Wu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Checkpoint inhibitors in bladder and renal cancers: results and perspectives
Fouad Aoun et al.
IMMUNOTHERAPY (2015)
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Douglas Marvel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Vishwanath Sathyanarayanan et al.
MOLECULAR ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
K. Cao et al.
ONCOGENE (2015)
A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
Monica Cojoc et al.
SEMINARS IN CANCER BIOLOGY (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Adoptive Cell Therapy-Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors
Steven A. Feldman et al.
SEMINARS IN ONCOLOGY (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics
Benjamin Bonavida et al.
REDOX BIOLOGY (2015)
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill et al.
IMMUNOLOGICAL REVIEWS (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
Julien Fourcade et al.
CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Mechanisms of Resistance Against Cancer Therapeutic Drugs
Shailja Chatterjee et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2014)
Cancer stem cells - important players in tumor therapy resistance
Selcuk Colak et al.
FEBS JOURNAL (2014)
B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look
Jenessa B. Smith et al.
GYNECOLOGIC ONCOLOGY (2014)
The use of endogenous T cells for adoptive transfer
Cassian Yee
IMMUNOLOGICAL REVIEWS (2014)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Michele Ardolino et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors
Sergey V. Ryzhov et al.
JOURNAL OF IMMUNOLOGY (2014)
Acquired and intrinsic resistance in cancer immunotherapy
Sander Kelderman et al.
MOLECULAR ONCOLOGY (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Interleukin-17 Facilitates the Immune Suppressor Capacity of High-Grade Glioma-Derived CD4 (+) CD25 (+) Foxp3 (+) T Cells Via Releasing Transforming Growth Factor Beta
H. Liang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Matthew D. Vesely et al.
RENAISSANCE OF CANCER IMMUNOTHERAPY (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau et al.
IMMUNOLOGY (2013)
Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells
Hirotomo Harimoto et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF- β1
Meriem Hasmim et al.
JOURNAL OF IMMUNOLOGY (2013)
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
James N. Kochenderfer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Lisa M. Coussens et al.
SCIENCE (2013)
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer
Robert Wesolowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
Asis Palazon et al.
CLINICAL CANCER RESEARCH (2012)
Therapeutic Antibodies Against Cancer
Mark J. Adler et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Strategies for Enhancing Vaccine-Induced CTL Antitumor Immune Responses
Xin Yong et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
被撤回的出版物: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
Evaluation of Current Cancer Immunotherapy Hemato-Oncology
Christopher S. Hourigan et al.
CANCER JOURNAL (2011)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8+ T-cell infiltration in the tumor
Katrin Singer et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells
Mario I. Vega et al.
LEUKEMIA & LYMPHOMA (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis
Laura M. Hix et al.
PLOS ONE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Ipilimumab attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Karl S. Peggs et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
R. Shimizu et al.
LEUKEMIA (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy
Arvind Chhabra
VACCINE (2010)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
Inhibition of Superoxide Generation upon T-Cell Receptor Engagement Rescues Mart-127-35-Reactive T Cells from Activation-Induced Cell Death
Hakan Norell et al.
CANCER RESEARCH (2009)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A. Rosenberg et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Cell Death in Tumors by Activating Caspases
A. Clark et al.
CURRENT CANCER DRUG TARGETS (2008)
Nuclear factor-kB activation: From bench to bedside
Gautam Sethi et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Modulation of the tumor cell phenotype by IFN-γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes
Kristian Hallermalm et al.
JOURNAL OF IMMUNOLOGY (2008)
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Jeremy B. Swann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel et al.
BLOOD (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
The role of regulatory T cells in ovarian cancer
J. Dietl et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
TNF-α induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction
Gira Raval et al.
JOURNAL OF IMMUNOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Nuclear factor-κ13 in development, prevention, and therapy of cancer
Carter Van Waes
CLINICAL CANCER RESEARCH (2007)
Regulatory T cells and cancer
Helen Y. Wang et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Interteukin-2 therapy of metastatic renal cell carcinoma- Predictors of response
David F. McDermott et al.
SEMINARS IN ONCOLOGY (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-κB activity:: Role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively
MI Vega et al.
JOURNAL OF IMMUNOLOGY (2005)
Toll-like receptors on tumor cells facilitate evasion of immune surveillance (Publication with Expression of Concern. See vol. 79, pg. 4305, 2019)
B Huang et al.
CANCER RESEARCH (2005)
Activation of NK cell cytotoxicity
MJ Smyth et al.
MOLECULAR IMMUNOLOGY (2005)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
Autocrine secretion of fas ligand shields tumor cells from fas-mediated killing by cytotoxic lymphocytes
K Hallermalm et al.
CANCER RESEARCH (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression
G Zhou et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity
L Arlettaz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Stromal fibroblasts in cancer initiation and progression
NA Bhowmick et al.
NATURE (2004)
Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function
J Thiery et al.
JOURNAL OF IMMUNOLOGY (2003)
Cutting edge: IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation
A Krug et al.
JOURNAL OF IMMUNOLOGY (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer
FR Villegas et al.
LUNG CANCER (2002)
Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy
D Montagna et al.
BLOOD (2001)
Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors
JP Medema et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Immune responses to tumour antigens:: implications for antigen specific immunotherapy of cancer
D Jäger et al.
JOURNAL OF CLINICAL PATHOLOGY (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
K Imai et al.
LANCET (2000)
Share Paper
